Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

At least five state committees in the US are exploring ways to enact independent measures to improve drug affordability.

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

With a lack of radiologists around the world, targeted uses of AI in Scotland are creating efficiencies in medical imaging.

LEO Pharma has applied to the EMA to expand the label for Anzupgo (delgocitinib) cream to include adolescents.

US-based private investment company SK Capital Partners’ affiliate is to invest in Swixx BioPharma to support its growth and ...

China’s focus on first or best-in-class oncology drugs and innovative R&D will help it to secure further licensing deals in ...

Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).